Granted Patent
B2
US 12,472,178 · App. 18/468,199 · Granted Nov 18, 2025
Amorphous solid dispersions
Assignee:
INTRA-CELLULAR THERAPIES, INC.
A61K31/4985A61K9/0019A61K9/0024A61K9/0053A61K9/1617A61K9/1635A61K9/1641A61K9/1652A61K9/2013A61K9/2027A61K9/2031A61K9/2054A61K9/4858A61K9/4866A61K47/38A61P3/04A61P25/06A61P25/18A61P25/22A61P25/24A61P25/28A61K9/10C07D471/16
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The disclosure provides new, stable, pharmaceutically acceptable amorphous solid dispersions of 1-(4-fluoro-phenyl)-4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one, together with methods of making and using them, and pharmaceutical compositions comprising them.
Claims (28)
1 . A method for the treatment of a human suffering from a disease or disorder selected from the group consisting of obesity, anorexia, bulimia, depression, anxiety, psychosis, schizophrenia, migraine, obsessive-compulsive disorder, sexual disorders, attention deficit disorder, attention deficit hyperactivity disorder, sleep disorders, conditions associated with cephalic pain, social phobias, and dementia, comprising administering to a patient in need thereof a therapeutically effective amount of an amorphous solid dispersion comprising 1-(4-fluoro-phenyl)-4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one (ITI-007) tosylate salt and a stabilizing excipient and optionally further comprising an anti-oxidant and/or a surfactant,
wherein the stabilizing excipient is selected from the group consisting of cellulose acetate phthalate, hydroxypropyl methyl cellulose acetate succinate, hydroxypropyl methyl cellulose phthalate, cellulose acetate, hydroxypropyl cellulose, polyvinyl acetate, polyvinyl pyrrolidone, polyvinyl pyrrolidone/vinyl acetate copolymer, and polyethylene glycol/polyvinyl acetate/polyvinylcaprolactam copolymer.
2 . The method of claim 1 , wherein the dispersion comprises ITI-007 tosylate salt and a stabilizing excipient selected from the group consisting of cellulose acetate phthalate, hydroxypropyl methyl cellulose acetate succinate, and hydroxypropyl methyl cellulose phthalate.
3 . The method of claim 1 , wherein the dispersion further comprises an anti-oxidant.
4 . The method of claim 1 , wherein the dispersion further comprises a surfactant.
5 . The method of claim 1 , wherein the dispersion is x-ray amorphous.
6 . The method according to claim 1 , wherein the amorphous solid dispersion is administered as a pharmaceutical composition comprising the dispersion, in combination or association with a pharmaceutically acceptable diluent or carrier.
7 . The method of claim 6 , wherein the composition is in the form of a tablet or capsule for oral administration.
8 . The method of claim 1 , wherein the disease or disorder is selected from the group consisting of depression, anxiety, psychosis, schizophrenia, obsessive-compulsive disorder, sexual disorders, attention deficit disorder, attention deficit hyperactivity disorder, sleep disorders, and dementia.
9 . A process for the production of the dispersion described in claim 1 comprising the steps of:
(a) combining 1-(4-fluoro-phenyl)-4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one (ITI-007) tosylate salt optionally in crystal form, with the selected excipient or excipients in a suitable solvent or mixture of solvents; and
(b) removing the solvent and recovering the amorphous solid dispersion thus formed.
10 . The method of claim 1 , wherein the dispersion has an X-ray diffraction pattern which is free of peaks characteristic of the excipient.
11 . The method of claim 1 , wherein the dispersion is manufactured by a method comprising dissolving ITI-007 tosylate salt and the selected excipient in a solvent or mixture of solvents and removing the solvent to obtain the amorphous solid dispersion.
12 . The method of claim 6 , wherein the composition is in the form of a depot formulation for use as a long-acting injectable (LAI).
13 . The method of claim 1 , wherein the stabilizing excipient is selected from the group consisting of:
(a) cellulose acetate phthalate, at a weight ratio of 10:90 to 40:60 or 35:65 to 65:35 of ITI-007 tosylate salt to cellulose acetate phthalate; or
(b) hydroxypropyl methyl cellulose acetate succinate (HPMC-AS), at a weight ratio of 10:90 to 40:60 of ITI-007 tosylate salt to HPMC-AS; or
(c) hydroxypropyl methyl cellulose phthalate (HPMC-P), at a weight ratio of 10:90 to 40:60 or 35:65 to 65:35 of ITI-007 tosylate salt to HPMC-P.
14 . The method of claim 1 , wherein the stabilizing excipient is selected from the group consisting of:
(a) cellulose acetate phthalate, at a weight ratio of 20:80 to 30:70 or 40:60 to 60:40 of ITI-007 tosylate salt to cellulose acetate phthalate; or
(b) hydroxypropyl methyl cellulose acetate succinate (HPMC-AS), at a weight ratio of 20:80 to 30:70 of ITI-007 tosylate salt to HPMC-AS; or
(c) hydroxypropyl methyl cellulose phthalate (HPMC-P), at a weight ratio of 20:80 to 30:70 or 40:60 to 60:40 of ITI-007 tosylate salt to HPMC-P.
15 . The method of claim 1 , wherein the stabilizing excipient is cellulose acetate phthalate, and wherein the dispersion comprises ITI-007 tosylate salt in admixture with the stabilizing excipient in a weight ratio of 25:75 or 50:50.
16 . The method of claim 1 , wherein the stabilizing excipient is hydroxypropyl methyl cellulose acetate succinate (HPMC-AS), and wherein the dispersion comprises ITI-007 tosylate salt in admixture with the stabilizing excipient in a weight ratio of 25:75.
17 . The method of claim 1 , wherein the stabilizing excipient is hydroxypropyl methyl cellulose phthalate (HPMC-P), and wherein the dispersion comprises ITI-007 tosylate salt in admixture with the stabilizing excipients in a weight ratio of 25:75 or 50:50.
18 . The method of claim 3 , wherein the anti-oxidant is selected from one or more of tocopherol, butylated hydroxytoluene (BHT), propyl gallate (OPG), and ascorbic acid.
19 . The method of claim 4 , wherein surfactant is an anionic or cationic or neutral surfactant.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Sep 15, 2023
From: LI, PENG
To: INTRA-CELLULAR THERAPIES, INC.
Reel/Frame 064924/0744 →
Continuity (5)
Continuation In Part
PCTUS2017054962
· Oct 3, 2017
Provisional Application
62407285
· Oct 12, 2016
References Cited (359)
US 2490813A
· Hughes et al.
· 1949
[cited by applicant]
US 3299078A
· Pachter
· 1967
[cited by applicant]
US 3813392A
· Sellstedt et al.
· 1974
[cited by applicant]
US 3914421A
· Rajagopalan
· 1975
[cited by applicant]
US 4001263A
· Plattner et al.
· 1977
[cited by applicant]
US 4115577A
· Rajagopalan
· 1978
[cited by applicant]
US 4183936A
· Rajagopalan
· 1980
[cited by applicant]
US 4219550A
· Rajagopalan
· 1980
[cited by applicant]
US 4238607A
· Rajagopalan
· 1980
[cited by applicant]
US 4389330A
· Tice et al.
· 1983
[cited by applicant]
US 4522944A
· Doria et al.
· 1985
[cited by applicant]
US 4530840A
· Tice et al.
· 1985
[cited by applicant]
US 4971971A
· Tokunaga et al.
· 1990
[cited by applicant]
US 4985432A
· Tokunaga et al.
· 1991
[cited by applicant]
US 5114976A
· Norden
· 1992
[cited by applicant]
US 5151419A
· Perenyi et al.
· 1992
[cited by applicant]
US 5538739A
· Bodmer et al.
· 1996
[cited by applicant]
US 5576460A
· Buchwald et al.
· 1996
[cited by applicant]
US 5648539A
· Goodbrand
· 1997
[cited by applicant]
US 5648542A
· Goodbrand et al.
· 1997
[cited by applicant]
US 5654482A
· Goodbrand
· 1997
[cited by applicant]
US 5705697A
· Goodbrand et al.
· 1998
[cited by applicant]
US 5723669A
· Goodbrand et al.
· 1998
[cited by applicant]
US 5723671A
· Goodbrand et al.
· 1998
[cited by applicant]
US 5847166A
· Buchwald et al.
· 1998
[cited by applicant]
US 5902901A
· Goodbrand et al.
· 1999
[cited by applicant]
US 6043370A
· Kubo et al.
· 2000
[cited by applicant]
US 6166226A
· Buchwald et al.
· 2000
[cited by applicant]
US 6235936B1
· Buchwald et al.
· 2001
[cited by applicant]
US 6307087B1
· Buchwald et al.
· 2001
[cited by applicant]
US 6323366B1
· Wolfe et al.
· 2001
[cited by applicant]
US 6395916B1
· Buchwald et al.
· 2002
[cited by applicant]
US 6407092B1
· Hester et al.
· 2002
[cited by applicant]
US 6465693B2
· Buchwald et al.
· 2002
[cited by applicant]
US 6541639B2
· Zhou et al.
· 2003
[cited by applicant]
US 6548493B1
· Robichaud et al.
· 2003
[cited by applicant]
US 6552017B1
· Robichaud et al.
· 2003
[cited by applicant]
US 6699852B2
· Robichaud et al.
· 2004
[cited by applicant]
US 6713471B1
· Robichaud et al.
· 2004
[cited by applicant]
US 6759554B2
· Buchwald et al.
· 2004
[cited by applicant]
US 6762329B2
· Marcoux et al.
· 2004
[cited by applicant]
US 6828314B2
· Frank et al.
· 2004
[cited by applicant]
US 6849619B2
· Robichaud et al.
· 2005
[cited by applicant]
US 6849640B2
· Ennis et al.
· 2005
[cited by applicant]
US 6867298B2
· Buchwald et al.
· 2005
[cited by applicant]
US 6888032B2
· Buchwald et al.
· 2005
[cited by applicant]
US 6946560B2
· Buchwald et al.
· 2005
[cited by applicant]
US 7026498B2
· Buchwald et al.
· 2006
[cited by applicant]
US 7071186B2
· Robichaud et al.
· 2006
[cited by applicant]
US 7081455B2
· Robichaud et al.
· 2006
[cited by applicant]
US 7109339B2
· Lee et al.
· 2006
[cited by applicant]
US 7115784B2
· Buchwald et al.
· 2006
[cited by applicant]
US 7183282B2
· Robichaud et al.
· 2007
[cited by applicant]
US 7223879B2
· Buchwald et al.
· 2007
[cited by applicant]
US RE39679E
· Robichaud et al.
· 2007
[cited by applicant]
US RE39680E
· Robichaud et al.
· 2007
[cited by applicant]
US 7238690B2
· Robichaud et al.
· 2007
[cited by applicant]
US 7247731B2
· Buchwald et al.
· 2007
[cited by applicant]
US 7323608B2
· Buchwald et al.
· 2008
[cited by applicant]
US 7375226B2
· Jolidon et al.
· 2008
[cited by applicant]
US 7462641B2
· Igo et al.
· 2008
[cited by applicant]
US 7580623B2
· Nuno et al.
· 2009
[cited by applicant]
US 7592454B2
· Lee et al.
· 2009
[cited by applicant]
US 7598273B2
· Gant et al.
· 2009
[cited by applicant]
US 7614727B2
· Hori
· 2009
[cited by applicant]
US 7645752B2
· McDevitt et al.
· 2010
[cited by applicant]
US 7750168B2
· Potyen et al.
· 2010
[cited by applicant]
US 7998971B2
· Barlow et al.
· 2011
[cited by applicant]
US 8309722B2
· Tomesch et al.
· 2012
[cited by applicant]
US 8309772B2
· Weiner et al.
· 2012
[cited by applicant]
US 8461148B2
· Hollander
· 2013
[cited by applicant]
US 8598119B2
· Mates et al.
· 2013
[cited by applicant]
US 8648077B2
· Tomesch et al.
· 2014
[cited by applicant]
US 8779139B2
· Tomesch et al.
· 2014
[cited by applicant]
US 8791138B2
· Seeman et al.
· 2014
[cited by applicant]
US 8993572B2
· Mates et al.
· 2015
[cited by applicant]
US 9168258B2
· Mates et al.
· 2015
[cited by applicant]
US 9199995B2
· Tomesch et al.
· 2015
[cited by applicant]
US 9315504B2
· Tomesch et al.
· 2016
[cited by applicant]
US 9371324B2
· Mates et al.
· 2016
[cited by applicant]
US 9393192B2
· Yam et al.
· 2016
[cited by applicant]
US 9427412B2
· Bryson et al.
· 2016
[cited by applicant]
US 9428506B2
· Mates et al.
· 2016
[cited by applicant]
US 9567327B2
· Xiong et al.
· 2017
[cited by applicant]
US 9586960B2
· Tomesch et al.
· 2017
[cited by applicant]
US 9616061B2
· Mates et al.
· 2017
[cited by applicant]
US 9708322B2
· Li et al.
· 2017
[cited by applicant]
US 9745300B2
· Mates et al.
· 2017
[cited by applicant]
US 9751883B2
· Tomesch et al.
· 2017
[cited by applicant]
US 9956227B2
· Vanover et al.
· 2018
[cited by applicant]
US 20010008942A1
· Buchwald et al.
· 2001
[cited by applicant]
US 20040034015A1
· Robichaud et al.
· 2004
[cited by applicant]
US 20040092534A1
· Yam et al.
· 2004
[cited by applicant]
US 20040127482A1
· Robichaud et al.
· 2004
[cited by applicant]
US 20040142970A1
· Chung et al.
· 2004
[cited by applicant]
US 20050166771A1
· Gygi et al.
· 2005
[cited by applicant]
US 20050222209A1
· Zeldis et al.
· 2005
[cited by applicant]
US 20050222238A1
· Alken
· 2005
[cited by applicant]
US 20060205787A1
· Muller et al.
· 2006
[cited by applicant]
US 20080069885A1
· Mesens et al.
· 2008
[cited by applicant]
US 20080132552A1
· Kleinman et al.
· 2008
[cited by applicant]
US 20080280941A1
· Lourtie
· 2008
[cited by applicant]
US 20110269777A1
· Bachurin et al.
· 2011
[cited by applicant]
US 20150004237A1
· Edgar et al.
· 2015
[cited by applicant]
US 20150031804A1
· Shiramizu et al.
· 2015
[cited by applicant]
US 20150071964A1
· Tang
· 2015
[cited by applicant]
US 20150080404A1
· Mates et al.
· 2015
[cited by applicant]
US 20180092864A1
· Martin et al.
· 2018
[cited by applicant]
CN 102105059A
· 2011
[cited by applicant]
CN 103209704A
· 2013
[cited by applicant]
EP 0058481
· 1982
[cited by applicant]
EP 0856508
· 1998
[cited by applicant]
EP 0976732
· 2000
[cited by applicant]
EP 1245553
· 2002
[cited by applicant]
EP 1254884
· 2002
[cited by applicant]
EP 1539115
· 2005
[cited by applicant]
EP 1564671
· 2005
[cited by applicant]
GB 1476087
· 1977
[cited by applicant]
GB 2145422
· 1985
[cited by applicant]
IN 201741021763
· 2018
[cited by applicant]
WO WO1994024125
· 1994
[cited by applicant]
WO WO1995013814
· 1995
[cited by applicant]
WO WO1995026325
· 1995
[cited by applicant]
WO WO1998015515
· 1998
[cited by applicant]
WO WO1998043956
· 1998
[cited by applicant]
WO WO1999043643
· 1999
[cited by applicant]
WO WO2000002887
· 2000
[cited by applicant]
WO WO2000035419
· 2000
[cited by applicant]
WO WO2000048610
· 2000
[cited by applicant]
WO WO2000064899
· 2000
[cited by applicant]
WO WO2000077001
· 2000
[cited by applicant]
WO WO2000077002
· 2000
[cited by applicant]
WO WO2000077010
· 2000
[cited by applicant]
WO WO2002059129
· 2002
[cited by applicant]
WO WO2002085838
· 2002
[cited by applicant]
WO WO2003014118
· 2003
[cited by applicant]
WO WO2004010981
· 2004
[cited by applicant]
WO WO2004013094
· 2004
[cited by applicant]
WO WO2004039788
· 2004
[cited by applicant]
WO WO2004045668
· 2004
[cited by applicant]
WO WO2004056324
· 2004
[cited by applicant]
WO WO2004064738
· 2004
[cited by applicant]
WO WO2006034187
· 2006
[cited by applicant]
WO WO2006081251
· 2006
[cited by applicant]
WO WO2006081332
· 2006
[cited by applicant]
WO WO2007025103
· 2007
[cited by applicant]
WO WO2007084841
· 2007
[cited by applicant]
WO WO2008112280
· 2008
[cited by applicant]
WO WO2009017836
· 2009
[cited by applicant]
WO WO2009100324
· 2009
[cited by applicant]
WO WO2009114181
· 2009
[cited by applicant]
WO WO2009145900
· 2009
[cited by applicant]
WO WO2011133224
· 2011
[cited by applicant]
WO WO2013155504
· 2013
[cited by applicant]
WO WO2013155505
· 2013
[cited by applicant]
WO WO2013155506
· 2013
[cited by applicant]
WO WO2014145192
· 2014
[cited by applicant]
WO WO2015085004
· 2015
[cited by applicant]
WO WO2015154025
· 2015
[cited by applicant]
WO WO2015154030
· 2015
[cited by applicant]
WO WO2015191554
· 2015
[cited by applicant]
WO WO2017132408
· 2017
[cited by applicant]
WO WO2017165755
· 2017
[cited by applicant]
WO WO2017165843
· 2017
[cited by applicant]
WO WO2017172811
· 2017
[cited by applicant]
WO WO2018031535
· 2018
[cited by applicant]
WO WO2018071233
· 2018
[cited by applicant]
WO WO2018189646
· 2018
[cited by applicant]
WO WO2019023062
· 2019
[cited by applicant]
WO WO2019236889
· 2019
[cited by applicant]
WO WO2019241278
· 2019
[cited by applicant]
Aiken, C., “An Overview of Atypical Antipsychotics for Bipolar Depression,” published on Jan. 3, 2020 at https://www.psychiatrictimes.com/view/overview-atypical-antipsychotics-bipolar-depression, 11 pages.
[cited by applicant]
Alvir, et al., “Clozapine-Induced Agranulocytosis,”
[cited by applicant]
Angst et al., “Prevalence and Characteristics of Undiagnosed Bipolar Disorders in Patients With a Major Depressive Episode,”
[cited by applicant]
Avendano, et al., “The problem of the existence of C(Ar)-H . . . N Intramolecular Hydrogen Bonds in a Family of 9-Azaphenyl-9H-carbazoles,”
[cited by applicant]
Balbach, et al., “Pharmaceutical evaluation of early development candidates ‘the 100 mg-approach’”,
[cited by applicant]
Bastin, et al.,“Salt Selection and Optimisation Procedures for Pharmaceutical New Chemical Entities”,
[cited by applicant]
Bechtold, D.A., et al., “Circadian Dysfunction in Disease,”
[cited by applicant]
Beletskaya, et al., “Pd- and Cu-catalyzed selective arylation of benzotriazole,”
[cited by applicant]
Bennett, J.C., et al., “Cecil Textbook of Medicine,” 20th Edition, vol. 1, pp. 1004-1010, (1996).
[cited by applicant]
Berger, et al., “Synthesis of some conformationally restricted analogs of fentanyl.”
[cited by applicant]
Boger, et al., “Inverse Electron Demand Diels-Alder Reactions of Heterocyclic Aza Dienes. Studies on the Total Synthesis of Lavendamycin: Investigative Studies on the Preparation of the CDE β-Carboline Ring System and A…
[cited by applicant]
Bowman, et al., “Intramolecular Aromatic Substitution (SRN1) Reactions—Use of Entrainment for the Preparation of Benzothiazoles,” Tetrahedron Letters, vol. 23, pp. 5093-5096, (1982).
[cited by applicant]
Bowman, et al., “Copper (1) Catalysed Aromatic Nucleophilic Substitution: A Mechanistic and Synthetic Comparison with the S
[cited by applicant]
Bowman, et al.,“Synthesis of 1H-quinazoline-4-ones Using Intramolecular Aromatic Nucelophilic Substitution,”
[cited by applicant]
Bremner, et al., “Neuroimaging of Posttraumatic Stress Disorder”,
[cited by applicant]
Bryan-Lluka, et al., “Potencies of Haloperidol Metabolites as Inhibitors of the Human Noradrenaline, Dopamine and Serotonin Transporters in Transfected COS-7 Cells”,
[cited by applicant]
Byrn, et al., “Pharmaceutical Solids: A Strategic Approach to Regulatory Considerations,”
[cited by applicant]
Caira, M.R., “Crystalline Polymorphism of Organic Compounds,”
[cited by applicant]
Cole, “ITI-007. 5-HT2A receptor antagonist, dopamine D2 receptor modulator, treatment of schizophrenia, treatment of insomnia,”
[cited by applicant]
Crawford, et al., “Copper-Catalyzed Amidations of Bromo Substituted Furans and Thiophenes,”
[cited by applicant]
Darmani, et al., “Do Functional Relationships Exist Between 5-HT
[cited by applicant]
Davis, et al., “ITI-007 in the Treatment of Schizophrenia: From Novel Pharmacology to Clinical Outcomes,”
[cited by applicant]
Davis et al. “ITI-007 demonstrates brain occupancy at serotonin 5-HT2A and dopamine D2 receptors and serotonin transporters using positron emission tomography in healthy volunteers”,
[cited by applicant]
Davis et al., “ITI-007: A Novel Treatment for Behavioral Disturbances Associated with Dementia and Related Disorders,” Clinical Trials in Alzheimer's Disease (CTAD) Congress 2014 (2014) (poster presentation).
[cited by applicant]
Davis et al., “Rationale for the Development of Low Doses of ITI-007 for the Treatment of Behavioral Disturbances Associated with Dementia,” The Journal of Prevention of Alzheimer's Disease, 2(4):302 (2015) (Clinical Tr…
[cited by applicant]
Davis, et al., “Lumateperone (ITI-007), A Novel Drug in Development for the Treatment of Agitation in Patients with Dementia, including Alzheimer's Disease: Rationale and Clinical Design,” The Journal of Prevention of A…
[cited by applicant]
Dhawan et al., “Sleep-related problems of Parkinson's disease,”
[cited by applicant]
Ellenbroek et al., “Animal Models for the Negative Symptoms of Schizophrenia,”
[cited by applicant]
Evindar, et al., “Copper- and Palladium-Catalyzed Intramolecular Aryl Guanidinylation: An Efficient Method for the Synthesis of 2-Aminobenzimidazoles”,
[cited by applicant]
Ezquerra, et al., “Efficient Reagents for the Synthesis of 5-, 7-, and 5, 7-Substitued Indoles Starting from Aromatic Amines: Scope and Limitations”,
[cited by applicant]
Fawcett, J., “Posttraumatic Stress Disorder, Stress, and Happiness”,
[cited by applicant]
Fee, et al., “Copper (II)-Promoted Solvolyses of Nickel (II) Complexes III. Tetradentate Schiff Base Ligands Containing Various Diamine Segments,”
[cited by applicant]
Ferreira, et al., “Novel Synthetic Routes to Thienocarbazoles via Palladium or Copper Catalyzed Amination or Amidation of Arylhalides and Intramolecular Cyclization”,
[cited by applicant]
Finet, et al., “Recent Advances in Ullmann Reaction: Copper (II) Diacetate Catalysed N-, )- and S-arylation Involving Polycoordinate Heteroatomic Derivatives,”
[cited by applicant]
Fletcher, P., et al., “Perceiving is Believing: A Bayesian Approach to Explaining the Positive Symptoms of Schizophrenia,”
[cited by applicant]
Foster, et al., “Acetylcholinesterase Inhibitors Reduce Spreading Activation in Dementia,”
[cited by applicant]
Friedman, M.J.., “Current and Future Drug Treatment for Posttraumatic Stress Disorder Patients”,
[cited by applicant]
Goodbrand, et al., “Ligand-Accelerated Catalysis of the Ullmann Condensation: Application to Hole Conducting Triarylamines,”
[cited by applicant]
Gramigna, J, “Lumateperone Safe, Effective for Depressive Symptoms Among Patients with Bipolar Disorders,”
[cited by applicant]
Grant, D., “Theory and Origin and Polymorphism”,
[cited by applicant]
Guillory, J.K., “Generation of Polymorphs, Hydrates, Solvates, and Amorphous Solids”,
[cited by applicant]
Hackam, et al., “Translation of Research Evidence from Animals to Humans,”
[cited by applicant]
Hamann, et al., “Systematic Variation of Bidentate Ligands Used in Aryl Halide Amination. Unexpected Effects of Steric, Electronic, and Geometric Perturbations”,
[cited by applicant]
Harbert, et al., “Neuroleptic Activity in 5-Aryltetrahydro-y-carbolines”,
[cited by applicant]
Hartwig, J., “Palladium-Catalyzed Amination of Aryl Halides: Mechanism and Rational Catalyst Design,”
[cited by applicant]
Harvey, et al., “Serotonin and Stress: Protective or Malevolent Actions in the Biobehavioral Response to Repeated Trauma?,”
[cited by applicant]
Hassan, et al., “Aryl-aryl Bond Formation One Century After the Discovery of the Ullmann Reaction,”
[cited by applicant]
Haynes, et al., “Occurrence of Pharmaceutically Acceptable Anions and Cations in the Cambridge Structural Database”,
[cited by applicant]
Hlavinka, E., “Schizophrenia Tx Eases Depression in Bipolar Disorder: Lumateperone Offers Greater Rate of Response, Remission versus Placebo,”
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2013/036514 issued Oct. 14, 2014.
[cited by applicant]
International Search Report issued in International Application No. PCT/US2008/003340, mailed Aug. 8, 2008, 3 pages.
[cited by applicant]
International Search Report issued in International Application No. PCT/US2009/001608, mailed Apr. 27, 2009, 3 pages.
[cited by applicant]
International Search Report issued in International Application No. PCT/US2009/003261, mailed Jul. 16, 2009.
[cited by applicant]
International Search Report issued in International Application No. PCT/US2011/00719, mailed Jul. 5, 2011, 3 pages.
[cited by applicant]
International Search Report issued in International Application No. PCT/US2013/036515, mailed Aug. 13, 2013, 3 pages.
[cited by applicant]
International Search Report issued in International Application No. PCT/US2013/036514, mailed Aug. 16, 2013, 3 pages.
[cited by applicant]
International Search Report issued in International Application No. PCT/US2013/036512, mailed Aug. 19, 2013, 4 pages.
[cited by applicant]
International Search Report issued in International Application No. PCT/US2017/054962, mailed Nov. 27, 2017, 3 pages.
[cited by applicant]
Ito, et al., “Studies of Organic Catalytic Reactions. VI. The Function of Pyridine and Copper in the Rosenmund-von Braun Reaction,”
[cited by applicant]
Izrayelit, L., “Schizoaffective Disorder and PTSD Successfully Treated With Olanzapine and Supportive Psychotherapy”,
[cited by applicant]
Jain et al., “Polymorphism in Pharmacy”,
[cited by applicant]
Ji, et al., “Selective Amination of Polyhalopyridines Catalyzed by a Palladium-xantphos Complex,”
[cited by applicant]
Jordan, V.C., “Tamoxifen: A Most Unlikely Pioneering Medicine,”
[cited by applicant]
Kahn, A., et al., “Residual Symptoms of Schiziphrenia. What are Realistic Treatment Goals? Lingering Symptoms Require you to Evaluate Pharmacotherapy and Offer Psychosocial Interventions,”
[cited by applicant]
Kametani, et al., “A Novel Synthesis of Indole Derivatives,”
[cited by applicant]
Kang, et al., “Copper-catalyzed N-arylation of Aryl Iodides with Benzamides or Nitrogen Heterocycles in the Presence of Ethylendiamine,”
[cited by applicant]
Kay, et al., “The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia,”
[cited by applicant]
Kessler, et al., “Lifetime Prevalence and Age-of-Onset Distributions of DSM-IV Disorders in the National Comorbidity Survey Replication,”
[cited by applicant]
Khorana, et al., “Gamma-Carbolines: Binding at 5-HT5A Serotonin Receptors,”
[cited by applicant]
Kiyomori, et al., “An Efficient Copper-catalyzed Coupling of Aryl Halides with Imidazoles,”
[cited by applicant]
Klapars, et al., “A General and Efficient Copper Catalyst for the Amidation of Aryl Halides and the N-arylation of Nitrogen Heterocycles,”
[cited by applicant]
Klapars, et al., “A General and Efficient Copper Catalyst for the Amidation of Aryl Halides,”
[cited by applicant]
Kondratov, et al., “Nucelophilic Substitution in the Aromatic Series. Lv. Reaction of o-nitrochlorobenzene with Ammonia in the Presence of Copper Compounds,”
[cited by applicant]
Koppel, et al., “Optimal Treatment of Alzheimer's Disease Psychosis: Challenges and Solutions,”
[cited by applicant]
Krystal, J.H., et al., “Adjunctive Risperidone Treatment for Antidepressant-Resistant Symptoms of Chronic Military Service-Related PTSD: A Randomized Trial,”
[cited by applicant]
Kwong, et al., “Mild and Efficient Copper-catalyzed Amination of Aryl Bromides with Primary Alkylamines,”
[cited by applicant]
Lammers et al., “Risperidone long-acting injection in Schizophrenia Spectrum Illnesses compared to first generation depot antipsychotics in an outpatient setting in Canada,”
[cited by applicant]
Laughren, et al., “Food and Drug Administration Commentary on Methodological Issues in Negative Symptom Trials,” Schizophrenia Bulletin, 37(2): 255-256 (2011).
[cited by applicant]
Lebert, et al., “Trazodone in Fronto-Temporal Dementia,”
[cited by applicant]
Lee, et al. “Novel, Highly Potent, Selective 5-HT
[cited by applicant]
Li, et al., “Discovery of a Tetracyclic Quinoxaline Derivative as a Potent and Orally Active Multifunctional Drug Candidate for the Treatment of Neuropsychiatric and Neurological Disorders,”
[cited by applicant]
Lieberman, et al., “ITI-007 for the Treatment of Schizophrenia: A 4-Week Randomized, Double-Blind, Controlled Trial,”
[cited by applicant]
Lin, et al., “Dosage and Duration of Antipsychotic Treatment in Demented Outpatients with Agitation or Psychosis,”
[cited by applicant]
Lipschitz, et al., “Childhood Posttraumatic Stress Disorder: A Review of Neurobiologic Sequelae,”
[cited by applicant]
Lopez, et al., “Psychiatric Symptoms Vary with the Severity of Dementia in Probably Alzheimer's Disease,”
[cited by applicant]
Louie, et al., “Palladium-Catalyzed Synthesis of Arylamines from Aryl Halides, Mechanistic Studies lead to Coupling in the Absence of Tin Reagents”,
[cited by applicant]
Lounkine, et al., “Formal Concept Analysis for the Identification of Molecular Fragment Combinations Specific for Active and Highly Potent Compounds,”
[cited by applicant]
Madhusoodanan, S., et al., “Pharmacological Management of Behavioral Symptoms Associated with Dementia,”
[cited by applicant]
Makadia et al., “Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier,”
[cited by applicant]
March, et al.,
[cited by applicant]
Marcoux, et al., “A General Copper-catalyzed Synthesis of Diaryl Ethers,”
[cited by applicant]
Marek et al., “Synergistic Action of 5-HT2A Antagonists and Selective Serotonin Reuptake Inhibitors in Neuropsychiatric Disorders,”
[cited by applicant]
Medisorb Microspheres Technology Fact Sheet, 2 pages (2009).
[cited by applicant]
Mohamed, et al., “Pharmacotherapy of PTSD in the U.S. Department of Veterans Affairs: Diagnostic- and Symptom-guided Drug Selection,”
[cited by applicant]
Mooter et al., “Drug Discovery Today Technologies,” vol. 9, No. 2, e79-e85 (2012).
[cited by applicant]
Morgan, et al., “Acoustic Startle in Individuals With Posttraumatic Stress Disorder,”
[cited by applicant]
Mueller, et al., “Detection of Depression in Acute Schizophrenia: Sensitivity and Specificity of 2 Standard Observer Rating Scales,”
[cited by applicant]
Mulrooney, et al., “Recent Developments in Copper-catalyzed N-arylation with Aryl Halides,”
[cited by applicant]
Murakami, et al., “Fischer Indolization of Ethyl Pyruvate 2-[2-(Trifluoromethyl) phenyl]-phenylhydrazone and New Insight into the Mechanism of the Goldberg Reaction,”
[cited by applicant]
Nagai, et al., “Synthesis of 2,3,4,4a,5,9b-hexahydro-1H-pyrido[4,3-b] indole Derivatives and Their Central Nervous System Activities,”
[cited by applicant]
Newman, et al., “Solid-state Analysis of the Active Pharmaceutical Ingredient in Drug Products,”
[cited by applicant]
Noble, F., et al., “The Opiod Receptors as Targets for Drug Abuse Medication,” British Journal of Pharmacology, vol. 172, pp. 3964-3979, (2015); DOI: 10.1111/bph.13190.
[cited by applicant]
O'Gorman, et al., “Lumateperone (ITI-007): A Novel Investigational Agent with Broad Therapeutic Potential Across Multiple Neuropsychiatric Disorders,” Poster p. 1.g.038, European College of Neuropsychopharmacology (ECNP…
[cited by applicant]
Palanisamy, M. et al., “Cellulose-Based Matrix Microspheres of Prednisolone Inclusion Complex; Preparation and Characterization.” American Association of Pharmaceutical Scientists PharmSciTech, vol. 12, No. 1, pp. 388-4…
[cited by applicant]
Perlis et al., “Clinical Features of Bipolar Depression Versus Major Depressive Disorder in Large Multicenter Trials”,
[cited by applicant]
Pieniaszek, et al., “Moricizine Bioavailability via Simultaneous Dual, Stable Isotope Administration: Bioequivalence Implications,”
[cited by applicant]
Pond, et al., “Stereospecific Reduction of Haloperidol in Human Tissues,”
[cited by applicant]
“Protection for the Amino Group,”
[cited by applicant]
PubChem, Open Chemistry Database, PubChem SID 103920954, PubChem CID 90655118, 6 pages (2011).
[cited by applicant]
Rackova, et al., “Free Radical Scavenging and Antioxidant Activities of Substituted Hexahydropyridoindoles. Quantitative Structure-Activity Relationships.”
[cited by applicant]
Rainer, M.K., “Risperidone Long-acting Injection: A Review of its Long Term Safety and Efficacy,”
[cited by applicant]
Rye (Sleep Disorders and Parkinson's Disease, 2000, accessed online http://www.waparkinsons.org/edu_research/articles/Sleep_Disorders.html), 2 pages.
[cited by applicant]
Sadighi, et al., “A Highly Active Palladium Catalyst System for the Arylation of Anilines,”
[cited by applicant]
Satlin, et al., “ITI-007 (Lumateperone) for the Treatment of Agitation in Patients with Dementia, including Alzheimer's Disease,” Alzheimer's & Dementia 14(7) (Suppl.): p. 678-79 (2018) (Alzheimer's Assoc. International…
[cited by applicant]
Satlin, et al., “ITI-007 (Lumateperone) for the Treatment of Agitation in Patients with Dementia, including Alzheimer's Disease,” Poster p. 2-032, Alzheimer's Assoc. International Conference 2018 (2018).
[cited by applicant]
Savjani, et al., “Drug Solubility: Importance and Enhancement Techniques,”
[cited by applicant]
Schennach, et al., “What Are Residual Symptoms in Schizophrenia Spectrum Disorder? Clinical Description and 1-year Persistence Within a Naturalistic Trial,”
[cited by applicant]
“Securities,” Bennett v. Alkermes, Inc., at http://securities.stanford.edu/filings-documents/1029/ALKS03-01/20031029_r01c_0312091.pdf (retrieved from the internet on Jun. 13, 2017), (2003).
[cited by applicant]
Seishinkei Shi, vol. 110, No. 7, pp. 557-584, (2008). Partial English translation only.
[cited by applicant]
Sigel, et al., “Tenary Complexes in Solution,”
[cited by applicant]
Singhal, et al., “Drug Polymorphism and Dosage Form Design: A Practical Perspective,”
[cited by applicant]
Skoog, et al.,
[cited by applicant]
Smith, et al., “Oxford Dictionary of Biochemistry and Molecular Biology”,
[cited by applicant]
Snyder, et al., “Functional Profile of a Novel Modulator of Serotonin, Dopamine, and Glutamate Neurotransmission,”
[cited by applicant]
Southwick, et al., “Neuroendocrine Alterations in Posttraumatic Stress Disorder,”
[cited by applicant]
“Study of a Novel Antipsychotic ITI-007 in Schizophrenia,” Clinical Trials.gov, 6 pages, Dec. 26, 2011.
[cited by applicant]
Sugahara, et al., “A Facile Copper-Catalyzed Ullman Condensation: N-Arylation of Heterocyclic Compounds Containing an—NHCO-Moiety,”
[cited by applicant]
Suzuki, H.et al., “Comparison of Nicotinamide, Ethyluirea and Polyethylene Glycol as Carriers for Nifedipine Solid Dirperssion Systems.” Chemical and Pharmaceutical Bulletin, vol. 45, No. 10, pp. 1688-1693, (1997).
[cited by applicant]
Taragano, et al., “A Double-Blind, Randomized, Fixed-Dose Trial of Fluoxetine vs. Amitriptyline in the Treatment of Major Depression Complicating Alzheimer's Disease,”
[cited by applicant]
Tariot, et al., “Memantine Treatment in Patients with Moderate to Severe Alzheimer Disease Already Receiving Donepezil: A Randomized Controlled Trail,”
[cited by applicant]
Tohen, M., et al., “Efficacy of Olanzapine and Olanzapine-Fluoxetine Combination in the Treatment of Bipolar I Depression,”
[cited by applicant]
Vanover, et al., “A Novel Approach to Address an Unmet Need in the Treatment of Schizophrenia and Depression: Lumateperone, an Innovative Modulator of Dopamine, Serotonin, and Glutamate,” Abstract presented at the Ameri…
[cited by applicant]
Vanover, et al., “Dopamine D2 receptor occupancy of lumateperone (ITI-007): a Positron Emission Tomography Study in patients with schizophrenia,” Neuropsychopharmacology 44:598-605, (2019).
[cited by applicant]
Vanover, K., et al., “ITI-007: A Novel Therapy for the Treatment of Schizophrenia and Related Psychoses,”
[cited by applicant]
Vyas, P., et al., “An Evaluation of Lumateperone Tosylate for the Treatment of Schizophrenia,”
[cited by applicant]
Wagaw, et al., “A Palladium-catalyzed Method for the Preparation of Indoles via the Fischer Indole Synthesis,”
[cited by applicant]
Warner-Schmidt JL. et al. “Antidepressant effects of selective serotonin reuptake inhibitors (SSRIs) are attenuated by anti-inflammatory drugs in mice and humans,”
[cited by applicant]
Wennogle, et al., “Activation of NMDA and AMPA Receptors by Lumateperone (ITI-007): Implications for Antidepressant Activity,” Abstract presented at the 2017 Collegium Internationale Neuro-Psychopharmacologicum (CINP) T…
[cited by applicant]
Weschules, et al., “Acetylcholinesterase Inhibitor and N-Methyl-D-Aspartic Acid Receptor Antagonist Use among Hospice Enrollees with a Primary Diagnosis of Dementia,”
[cited by applicant]
Wiese, M., “DSC Detection of Polymorphism in Pharmaceutical Anhdrous Dexamethasone Acetate,”
[cited by applicant]
Wolfe, et al., “An Improved Catalyst System for Aromatic Carbon-nitrogen Bond Formation: The Possible Involvement of bis(phosphine) Palladium Complexes as Key Intermediates,”
[cited by applicant]
Wolfe, et al., “Intramolecular Palladium-catalyzed Aryl Amination and Aryl Amidation,”
[cited by applicant]
Wolter, et al., “Synthesis of N-aryl Hydrazides by Copper-catalyzed Coupling of Hydrazides with Aryl Iodides,”
[cited by applicant]
Written Opinion of the International Searching Authority for International Application No. PCT/US2013/036514 mailed Aug. 16, 2013, 4 pages.
[cited by applicant]
Written Opinion of the International Searching Authority for International Application No. PCT/US2017/54962 mailed Nov. 27, 2017, 8 pages.
[cited by applicant]
Yamada, et al., “A Mild Copper-mediated Intramolecular Amination of Aryl Halides,”
[cited by applicant]
Yang, B.H., “The Development of Efficient Protocols for the Palladium-catalyzed Cyclization Reactions of Secondary Amides and Carbamates,”
[cited by applicant]
Yudofsky, et al., “Propranolol in the Treatment of Rage and Violent Behavior in Patients with Chronic Brain Syndromes,”
[cited by applicant]
Zhang, G., et al., “The Role of Serotonin 5-HT2A Receptors in Memory and Cognition,” Front. Pharmacol., vol. 6, No. 225, pp. 1-17, (2015); DOI: 10.3389/fphar.2015.00225.
[cited by applicant]
Zhang, et al., “Highly Efficient Copper-catalyzed N-arylation of Alkylamines with Aryl Iodides Using Phosphoramidite as Ligand,”
[cited by applicant]
Press Release, “Intra-Cellular Therapies Announces Additional Results from Phase I/II Clinical Trial for ITI-007 in Healthy Geriatric Subjects and Patients With Dementia,” Intra-Cellular Therapies, Press Release Date: N…
[cited by applicant]
Pine, A. et al., “Dopamine, Time, and Impulsivity in Humans,” The Journal of Neuroscience, vol. 30, pp. 8888-8896, (2010).
[cited by applicant]